17,261 trials
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 · Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Primary: Participants With a Response — 3 Participants
Alopecia Areata
Primary: Change in Gene Expression Th2/IL-13, "T22"/IL-22, S100A7 and S100A8, Th1/IFN-gamma, and Th17/IL-17A Jointly Correlated — -0.28 z-score
Primary Systemic Amyloidosis
Primary: Hematologic Response — 6; 3; 11; 5 Participants
Infections, Bacterial
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Zero (Pre-dose) Over the Dosing Interval (AUC[0-tau]) of Gepotidacin — 20236.2; 29313.8 Hours* nanogram per…
Blood Stem Cell Transplant Failure · Leukemia · Hematologic Malignancies
Primary: Number of Participants With Non-relapse Mortality (NRM) — 8; 7; 2; 0 Participants
Obesity and Diabetes Mellitus, Type 2
Primary: Percent Change From Baseline in Body Weight at Week 12 — -0.70; -5.25; -6.55; -7.92 Percent Change — p=<.001
Healthy Volunteer
Primary: Subject-reported Visual Analog Scale (VAS) Pain Score Following Tympanic Membrane Tap for Subjects Treated With Active Tymbion Iontophoresis Compared to VAS Score for…
Rupture of Anterior Cruciate Ligament
Primary: Normative Isokinetic Knee Extension Strength, Measured in Newton Meters (Nm) at 26 Weeks Post-op — 0.881; 0.681 Nm — p=0.0498
Hematologic Malignancies · Relapse · Graft-Versus-Host Disease
Primary: Phase I: Maximum Tolerated Dose (MTD) of Carfilzomib — 36 milligrams per square meter (mg/m^2)
Leukemia
Primary: Participants With a Response CR + PR + CRi — 4; 1; 4 Participants
Graft Versus Host Disease · GVHD
Primary: Number of Participants Stratified by Acute Graft Versus Host Disease GVHD Stage — 6; 1 Participants
Coronary Heart Disease
Primary: Percent Change From Baseline in HDL-C — 33.76; 3.69 Percentage Change of HDL-C
Lung Diseases, Interstitial
Primary: Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period — -17.9; 116.6; -90.3; 125.6 milliliter (mL) — p=0.6777
Coronary Heart Disease
Primary: Percent Change From Baseline in Mean Wall Thickness — 4.245; 6.679 Percent Change
HIV Infections
Primary: Mean Logarithm With Base 10 (Log10) Change From Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Day 9 — -1.3445; -1.2532; -1.2381; -1.1888 Log10…